Several classes of medication can cause eye floaters, and they do so through surprisingly different mechanisms. Some drugs physically deposit material inside the eye, others trigger inflammation that creates visible debris, and still others increase the likelihood of bleeding or retinal tears that produce floater-like symptoms. The list spans common prescriptions like blood thinners and antidepressants as well as specialized treatments like eye injections and cancer drugs, and the clinical significance ranges from a harmless nuisance to a warning sign of serious eye damage.
Intravitreal Injections and Silicone Oil Droplets
The most direct way a medication causes floaters is by injecting material straight into the vitreous, the gel-like substance that fills the eye. Anti-VEGF drugs like bevacizumab, ranibizumab, and aflibercept are given this way to treat conditions such as diabetic macular edema and age-related macular degeneration. The drugs themselves dissolve, but the syringes used to deliver them are lubricated with silicone oil, and tiny droplets of that oil can shed into the vitreous during the injection. These droplets show up as small, shimmering, iridescent floaters that patients sometimes notice immediately.
Most silicone oil droplets are too small to bother anyone, but in rare cases they cause persistent visual disturbance. One case report described a 54-year-old man who developed pain and iridescent floaters right after a single bevacizumab injection; examination confirmed multiple silicone oil droplets floating in his vitreous cavity, and his symptoms lasted at least four weeks.1PubMed Central. Silicone Oil Droplets in the Vitreous After an Anti-vascular Endothelial Growth Factor (VEGF) Injection: A Complication of Syringe Lubrication Several factors make silicone shedding more likely, including freeze-thaw cycles during drug storage, mechanical shaking, and improper handling of the syringe plunger.2PubMed Central. Silicone Oil Migration During Intravitreal Anti-Vascular Endothelial Growth Factor Injections: A Review of Clinical Evidence and Factors Related to Transmission
Intravitreal Corticosteroids and Preservative Reactions
Corticosteroids injected directly into the eye present a double source of floaters. Triamcinolone acetonide, one of the most widely used intravitreal steroids, is a suspension of white crystalline particles. After injection, those particles are often visible to the patient as floaters, especially in the first few weeks while the drug is dissolving. One study tracking patients after intravitreal injections found that about a third of patients reported floaters immediately after the procedure, and by the two-week follow-up roughly two thirds reported them.3PubMed Central. Visual perceptions induced by intravitreous injections of therapeutic agents
Beyond the drug particles themselves, the preservatives used in some triamcinolone formulations can irritate the eye. Benzyl alcohol, a common preservative, has been shown to be toxic to retinal cells in laboratory studies, and preservative-related reactions can produce vitreous opacities that look and behave like floaters.4BMC Ophthalmology. Vitreous opacities after intravitreal triamcinolone injection- a case report Preservative-free formulations were developed partly to reduce this problem, though the crystalline drug particles still produce visible floaters in many patients regardless.
Fluoroquinolone Antibiotics
Oral fluoroquinolones like ciprofloxacin, levofloxacin, and moxifloxacin made headlines over a decade ago when a large study linked them to a roughly fourfold increase in the risk of retinal detachment. That 2012 study found that patients currently using fluoroquinolones had a higher rate of retinal detachment compared with nonusers, though the absolute risk remained small.5JAMA Ophthalmology. Flashes, Floaters, and Oral Fluoroquinolones Retinal detachment is typically preceded by a sudden burst of floaters and flashing lights, so fluoroquinolones became associated with those symptoms as well.
The story got more complicated as follow-up studies failed to confirm the link. A population-based study found no increased risk of retinal detachment or symptomatic retinal breaks with fluoroquinolone use.6PubMed Central. Oral fluoroquinolones and the incidence of rhegmatogenous retinal detachment and symptomatic retinal breaks: a population-based study A later retrospective analysis of three large healthcare databases also found no association between fluoroquinolones and retinal detachment.7PubMed Central. Risk of retinal detachment and exposure to fluoroquinolones, common antibiotics, and febrile illness using a self-controlled case series study design: Retrospective analyses of three large healthcare databases in the US The original finding may have reflected confounding by the infections fluoroquinolones were prescribed for, since febrile illness itself can trigger changes in the vitreous.
Where this leaves the average patient: if you notice new floaters while taking ciprofloxacin or a similar antibiotic, it is worth mentioning to your doctor, but the weight of evidence at this point does not firmly establish that fluoroquinolones directly cause floaters or retinal detachment. The original study raised a legitimate concern, and the question is not fully settled, but several larger analyses have been unable to reproduce the finding.
Blood Thinners and Vitreous Hemorrhage
Anticoagulants and antiplatelet drugs do not cause classic vitreous floaters on their own, but they can amplify the bleeding that happens when the vitreous gel naturally separates from the retina. This separation, called posterior vitreous detachment, happens to most people as they age and often produces a few benign floaters. In patients taking aspirin, clopidogrel, or warfarin, though, that process is more likely to include bleeding into the vitreous.8PubMed. Oral anticoagulation and the risk of vitreous hemorrhage and retinal tears in eyes with acute posterior vitreous detachment Blood in the vitreous casts dark, often moving shadows across vision that patients describe as floaters, cobwebs, or a reddish haze.
This does not mean blood thinners should be stopped to prevent floaters. The cardiovascular benefits of these medications almost always outweigh the eye-related risks. But it does mean that if you are on anticoagulant therapy and experience a sudden shower of new floaters, the urgency of getting your eyes examined is somewhat higher, because the chance of significant vitreous hemorrhage is greater than it would be for someone not on these drugs.
Medications That Trigger Intraocular Inflammation
A number of systemic medications can cause uveitis, an inflammatory condition inside the eye that commonly produces floaters along with redness, pain, light sensitivity, and blurred vision. The inflammatory cells and protein that accumulate in the vitreous during uveitis are what the patient sees as floaters. Drug-induced uveitis has been documented with a surprisingly varied list of medications. Rifabutin, an antibiotic used in HIV/AIDS patients, became one of the most recognized culprits. Others include cidofovir (an antiviral), bisphosphonates like pamidronate, sulfonamide antibiotics, and even some interleukins used in immunotherapy.9PubMed. Drug-induced uveitis: Incidence, prevention and treatment
Among the bisphosphonates, alendronate (commonly prescribed for osteoporosis) has been linked to ocular inflammation that includes floaters. One case report described a 71-year-old woman who developed floaters in both eyes about three months after starting alendronate, and examination revealed chorioretinitis, an inflammation affecting the choroid and retina.10American Journal of Ophthalmology Case Reports. Alendronate induced chorioretinitis: The importance of meticulous assessments The timing and resolution after stopping the drug pointed strongly to the medication as the cause. Bisphosphonate-related eye inflammation is uncommon but well-documented enough that ophthalmologists consider it in patients who develop unexplained uveitis while on these drugs.
The floaters from drug-induced uveitis usually resolve once the offending medication is stopped and the inflammation is treated, though the timeline varies. In cases where the inflammation is caught early, recovery tends to be complete. In delayed or severe cases, structural damage to the eye can leave permanent visual changes.
Tamoxifen
Tamoxifen, a hormonal therapy used widely in breast cancer treatment, is known to cause a form of retinal toxicity at higher or prolonged doses. The classic finding on examination is crystalline deposits in the retina, but some patients develop inflammatory changes as well. In one reported case, a 49-year-old woman developed bilateral floaters just two months after starting tamoxifen at the standard dose of 20 mg per day, and her examination showed both retinopathy and intermediate uveitis.11Journal Français d’Ophtalmologie. A case of tamoxifen retinopathy associated with intermediate uveitis
Tamoxifen retinopathy is typically associated with cumulative doses, so it is more common in patients who have been on the drug for years. The fact that floaters can appear within weeks suggests that some individuals may be unusually sensitive or that the inflammatory component of tamoxifen’s ocular effects can emerge earlier than the crystalline deposits. Patients on long-term tamoxifen are generally advised to have periodic eye exams, and floaters are one of the symptoms that should prompt an earlier visit.
SSRI Antidepressants
Selective serotonin reuptake inhibitors, the most commonly prescribed class of antidepressants, have been linked to a range of visual complaints. A study collecting patient-reported visual problems associated with SSRIs found that floaters were reported by about one in six patients who developed visual symptoms on these drugs.12PubMed. Development and persistence of patient-reported visual problems associated with serotonin reuptake inhibiting antidepressants Blurred vision was the most common complaint, followed by night blindness, floaters, and light sensitivity.
What makes SSRI-related visual symptoms particularly frustrating is that they sometimes persist even after the medication is discontinued. In the same study, 49 patients reported enduring vision problems after stopping treatment.12PubMed. Development and persistence of patient-reported visual problems associated with serotonin reuptake inhibiting antidepressants The mechanism behind SSRI-related floaters is not well understood. Serotonin receptors exist in the retina, and there is speculation that changes in serotonin signaling could affect the vitreous or retinal function in ways that produce visual phenomena, but this remains an area where the evidence is thin. The practical takeaway is that if you notice new floaters shortly after starting or changing an SSRI, it is worth reporting to your prescriber, though for most people the visual symptoms are mild enough that they do not warrant stopping a medication that is helping with depression or anxiety.
Eye Drops That Can Cause Floaters
Two types of prescription eye drops deserve mention. Pilocarpine, a pupil-constricting drop used historically for glaucoma and more recently in a newer formulation for age-related difficulty with near vision, can trigger floaters through a mechanical process. When pilocarpine contracts the ciliary muscle inside the eye, it can pull on the vitreous and retina. In susceptible individuals, this traction can cause a retinal tear or even a vitreous detachment. One case report documented a man who developed eye pain, hazy vision, and floaters within minutes of using a pilocarpine drop, and examination revealed a horseshoe-shaped retinal tear along with vitreous hemorrhage.13PubMed Central. Horseshoe Retinal Tear Minutes After Use of a New Pilocarpine Formulation in a Presbyopic, Emmetropic Man This is an uncommon but serious complication, and it highlights why even a seemingly simple eye drop can have retinal consequences.
Oxymetazoline eye drops, approved for treating droopy eyelids, have also been associated with vitreoretinal complications in post-marketing surveillance. An analysis of adverse events reported to the FDA identified cases of vitreous floaters, vitreous detachment, retinal detachment, and vitreous hemorrhage among users, all at low rates but statistically more frequent than would be expected by chance.14Ophthalmic Plastic & Reconstructive Surgery. Safety Analysis of Oxymetazoline Eye Drops for Blepharoptosis Using the FDA Adverse Event Reporting System The same analysis found an unexpectedly high rate of mydriasis (pupil dilation) with these drops. One plausible explanation is that wider pupils allow more light into the eye and make pre-existing vitreous opacities suddenly noticeable, essentially unmasking floaters that were already there rather than creating new ones. But the retinal detachment and hemorrhage cases suggest that something beyond simple optical unmasking may also be at play.
How to Tell If a Medication Is Causing Your Floaters
Drug-related floaters do not look fundamentally different from the age-related kind. You will see the same drifting specks, strands, or cobwebs moving across your field of vision. The clue that a medication is involved is usually timing: the floaters appear shortly after starting a new drug or changing a dose. With intravitreal injections, the connection is obvious because the symptoms begin within hours or days. With systemic medications like bisphosphonates, antidepressants, or tamoxifen, the onset can be weeks to months after starting treatment, which makes the link harder to spot.
If you suspect a medication is behind new floaters, the most important step is an eye exam rather than stopping the drug on your own. Many of the mechanisms described above, from vitreous hemorrhage to retinal tears to uveitis, require specific treatment. Simply discontinuing the medication may or may not resolve the floaters, and in some cases (like a retinal tear from pilocarpine-induced traction) delaying proper treatment can lead to retinal detachment.
When Drug-Related Floaters Signal an Emergency
A gradual increase in a few small floaters is usually not urgent, regardless of whether medication is involved. But certain patterns demand same-day evaluation:
- Sudden shower of floaters: Dozens of new floaters appearing at once, especially accompanied by flashing lights, can mean a retinal tear or detachment.
- Dark curtain or shadow: A shadow creeping across part of your visual field suggests the retina is pulling away and needs emergency repair.
- Red or dark haze: A diffuse darkening of vision, sometimes with a reddish tint, points to vitreous hemorrhage, particularly relevant for patients on blood thinners.
- Pain and redness: Floaters combined with a red, painful eye suggest inflammation such as drug-induced uveitis, which needs prompt treatment to prevent permanent damage.
Patients taking anticoagulants, those who have recently had an intravitreal injection, and those on pilocarpine drops are at somewhat higher risk of the more serious causes. For these groups especially, new floaters should not be dismissed as a benign nuisance without at least a dilated eye exam to rule out bleeding or retinal damage.
Why Drug-Related Floaters Are Underreported
One of the frustrating aspects of this topic is how little systematic data exists. Most of what we know comes from case reports, post-marketing surveillance databases like the FDA’s adverse event reporting system, and patient surveys rather than from controlled clinical trials designed to track floaters as an outcome. Floaters are subjective, difficult to quantify, and easy to overlook in trials focused on more severe endpoints like vision loss or retinal detachment. A patient in a clinical trial for an antidepressant, for instance, is unlikely to have a dilated eye exam at every visit, and even if they report floaters, those reports often end up as minor footnotes in safety data.
This reporting gap means the true frequency of medication-related floaters is almost certainly higher than published figures suggest. It also means that for several of the drug classes discussed here, the evidence is strong enough to say “this drug can cause floaters in some people” but not strong enough to say exactly how often it happens. Patients who develop unexplained floaters on any systemic medication should consider the possibility that the drug is involved, even if floaters are not listed as a known side effect in the prescribing information.